Asthma Drug Can Block SARS-Cov-2 Protein Finds IISC Researchers

The team plans to work with chemists to see if they can modify the structure of the drug to make it more potent against SARS-CoV-2.

The Government of India has placed the order of one crore doses of ZyuCoV-D with Zydus Cadila.

“Promising Breakthrough: Common Asthma Drug Montelukast Emerges as Potential Weapon Against SARS-CoV-2, IISc Study Finds”

In a groundbreaking revelation, researchers at the Indian Institute of Science (IISc) in Bengaluru have unveiled a remarkable new dimension to the fight against the relentless SARS-CoV-2 virus. Their study, which has sent ripples of excitement through the medical community, highlights the potential of an unexpected contender in the battle against COVID-19: montelukast, a well-established drug used to treat asthma and allergies.

“Repurposing Montelukast: From Inflammation Fighter to Potential COVID-19 Combatant, Backed by FDA Approval”

Montelukast, a mainstay in the medical arsenal for over two decades with its approval by the US Food and Drug Administration (FDA), has primarily been employed to quell the fires of inflammation ignited by ailments like asthma, hay fever, and hives. However, this seemingly unassuming drug has now taken on a new role as a potential warrior against the  virus wreaking havoc across the globe.

“Unlocking New Defenses: Montelukast’s Protein Binding Ability Offers Innovative Approach to Curtailing SARS-CoV-2 Replication”

The study’s revelation stems from montelukast’s ability to bind to a critical protein produced by the SARS-CoV-2 virus, effectively putting the brakes on its replication within human immune cells. This pivotal discovery offers a fresh perspective on combatting the virus by hindering its propagation at a cellular level.

The SARS-CoV-2 protein in question, known as Nsp1, emerges as one of the virus’s initial foot soldiers upon invading the human body. This protein can latch onto ribosomes within our immune cells, curbing the synthesis of vital proteins imperative for the immune system’s robust functioning. The consequence is a weakened defense, allowing the virus to flourish unchecked. With montelukast’s intervention targeting Nsp1, a potential strategy to curtail the virus’s malevolent spread comes into view.

“Charting a Course for Success: Researchers Set to Amplify Montelukast’s Impact on SARS-CoV-2 by Fine-Tuning Its Structure in Collaboration with Chemists.

The researchers’ roadmap is clear: collaborate with chemists to enhance the drug’s efficacy against SARS-CoV-2 by refining its structural composition. This pursuit of potency reflects their dedication to unearthing every possible means to subdue the virus. Concurrently, the team remains resolute in their quest for other compounds displaying similar potent antiviral capabilities, underscoring their commitment to fortify our defenses against current and future viral adversaries.

“A Bright Ray of Hope: Montelukast’s Remarkable Transition from Asthma Aid to COVID-19 Warrior, Bolstered by FDA Support, Exemplifies Scientific Ingenuity and Resilience in Preserving Global Well-being”

As the world grapples with the ever-evolving challenges posed by the pandemic, this study stands as a beacon of hope, showcasing how an old ally like montelukast can be repurposed in the battle against COVID-19. With the weighty endorsement of the FDA behind it, montelukast’s journey from asthma relief to viral adversary underscores the remarkable ingenuity and resilience of the scientific community as it strives to safeguard human health.

Read More: Study Reveals Long-Term Heart Health Benefits Of Breastfeeding For Mothers

Facebook Comments